Cencora, Inc. (NYSE:COR) Shares Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. increased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 46.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,245 shares of the company's stock after purchasing an additional 1,995 shares during the period. Vontobel Holding Ltd.'s holdings in Cencora were worth $1,403,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in COR. Pacer Advisors Inc. raised its holdings in shares of Cencora by 6,855.3% in the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock worth $464,874,000 after buying an additional 2,035,679 shares during the period. Wellington Management Group LLP increased its stake in Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after purchasing an additional 338,452 shares during the period. Nordea Investment Management AB increased its stake in Cencora by 40.2% in the fourth quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock worth $243,173,000 after purchasing an additional 308,773 shares during the period. Two Sigma Advisers LP lifted its position in shares of Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock worth $368,771,000 after purchasing an additional 292,600 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Cencora by 3.8% during the third quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after purchasing an additional 291,867 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

COR has been the topic of several recent analyst reports. Wells Fargo & Company raised their price target on shares of Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research note on Wednesday, January 29th. Mizuho began coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. Robert W. Baird boosted their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, Barclays lifted their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and a consensus price target of $277.90.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.80% of the company's stock.

Cencora Stock Down 0.8 %

Cencora stock traded down $1.99 during mid-day trading on Friday, reaching $241.47. 1,060,827 shares of the company were exchanged, compared to its average volume of 1,488,495. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a market cap of $46.83 billion, a P/E ratio of 34.35, a PEG ratio of 1.32 and a beta of 0.49. The business has a fifty day moving average of $239.52 and a 200 day moving average of $237.46. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.